MDS/CMML Unfiltered: Ask Dr. Afaf Osman

Dalton joined HealthTree in 2024 as the MPNs and MDS Program Manager. He is passionate about helping patients gain a better understanding of their health and treatment and sees it as a way to help empower individuals and their families who are affected by these diseases. Prior to joining HealthTree Dalton earned a Master’s Degree in Oncological Sciences while studying various different blood cancers. When not interacting with patients he is an avid snowboarder and hiker.

Dr. Afaf E. Osman is an Assistant Professor specializing in Hematology and Hematologic Malignancies within the Division of Hematology at the University of Utah. Board certified in Hematology and Medical Oncology, Dr. Osman focuses on the diagnosis, management, and underlying mechanisms of clonal hematopoiesis, myeloid malignancies, and bone marrow failure syndromes. After completing her Internal Medicine residency at Johns Hopkins University and Hematology and Oncology fellowship at the University of Chicago, Dr. Osman joined the faculty at the University of Utah in 2020. She is actively involved in multi-institutional studies and clinical trials aimed at improving the understanding and treatment of conditions such as acute myeloid leukemia (AML) and clonal cytopenias of undetermined significance (CCUS). Dr. Osman's research centers on uncovering the genetic and inflammatory drivers of myeloid malignancies, with a focus on how these factors contribute to disease progression and therapeutic resistance. Her work emphasizes translating laboratory findings into clinical strategies to enhance patient outcomes. Dr. Osman is a member of American Society of Hematology, Society of Hematologic Oncology, and American Society of Clinical Oncology.